Core Points - Clearmind Medicine Inc. received a Notification Letter from Nasdaq indicating non-compliance with Listing Rule 5550(b)(1) due to insufficient stockholders' equity [1][2] - The company's stockholders' equity was reported at $1,065,668, below the required minimum of $2,500,000 [2] - The Notification Letter does not immediately affect the company's listing status, and shares continue to trade under the symbol "CMND" [3] Compliance Plan - Clearmind has 45 days to submit a plan to regain compliance, with a deadline of December 18, 2025 [3] - If the plan is accepted, Nasdaq may grant an extension of up to 180 days to demonstrate compliance [3] - The company is exploring various options to regain compliance and intends to submit the plan as soon as possible [4] Financial Strategies - The company entered into securities purchase agreements to issue convertible promissory notes totaling up to $10,000,000 [5] - As of late October 2025, $1,045,062 of these notes were converted into 885,000 common shares [5] - The company expects that further conversions of the notes will help meet Nasdaq's stockholders' equity requirement [5] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics for under-treated health issues [6] - The company holds a portfolio of nineteen patent families, including 31 granted patents, and aims to expand its intellectual property [7]